O ptimal management of major depressive disorders is enhanced by applying a chronic illnessmanagement model with precise and measurable therapeutic endpoints. 1 In contradistinction to several other chronic medical disorders, biological markers of illness activity in depression do not currently exist. In the interim, therapeutic progress is monitored by evaluating changes in the severity of depressive symptoms and in functional domains. This concatenation of findings is particularly disconcerting in view of the fact that most depressed patients in either primary care or psychiatric settings are not systematically evaluated with objective quantifiable measures -a modifiable deficiency in patient management. [2] [3] [4] [5] [6] The most frequently reported symptomatic outcome measure in clinical trials of antidepressants has been response to treatment, arbitrarily defined as a reduction of 50% or more in total symptom severity from a pretreatment assessment of the patient's depression. 7 A categorical response to therapy that fails to achieve a fully asympomatic remitted state furnishes an unsatisfactory outcome, in that it includes patients with ongoing disease activity that is clinically significant. Patients who show improvement in symptom severity but are not asymptomatic are at risk for developing chronic depression, and continue to be vulnerable to poor outcomes and comorbid medical disorders. [8] [9] [10] Remission is an objective outcome indicated by a quantifiable score with a depressive symptom measurement tool. In antidepressant clinical trials, the 17-item Hamilton Depression Rating Scale (HAMD-17) has been the "gold standard" for use. HAMD-17, however, has not been accepted by clinicians for many reasons, 11,12 notably psychometric deficiencies and the length of time needed to administer it.
tive to change after 8 weeks of antidepressant efficacy formed the constituent items of HAMD-7 (Appendix 1). A remission cut-off score for HAMD-7 that correlated with HAMD-17 ≤ 7 was also determined (Appendix 2). 1,14 HAMD-7 required minutes to administer and served as an efficient and reliable measure of therapeutic progress and symptomatic remission.
Our main objective in this study was to validate the HAMD-7 scale in a primary care setting by comparing its psychometric properties with those of 2 accepted measurement tools, HAMD-17 and the Montgomery-Asberg Depression Rating Scale (MADRS).
Methods
We identified English-or French-speaking patients 18 years of age or older who met the criteria for a major depressive disorder (a minimum baseline HAMD-17 score 18, whether single-episode or recurrent) as defined in the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision (DSM-IV-TR). 19 Patients with current psychiatric or medical comorbidity were eligible only if the comorbid condition was not the primary focus of clinical attention. Eligible patients provided written informed consent.
We excluded patients if their depression was chronic ( 2 years of syndromal severity) or resistant to treatment (failure to respond to more than 2 antidepressants of dissimilar classes), or who had a primary clinical diagnosis other than DSM-IV-TR major depressive disorder (e.g., bipolar disorder). We also excluded patients who were pregnant or lactating, had clinically significant and unstable medical diseases (such as cardiovascular or neurological disorders), were judged to be at significant risk for suicide, or met DSM-IV-TR criteria for substance abuse or dependence during the past 3 months.
To act as primary care investigators in the study, we recruited people with office-based practices in any of Canada's 4 most populous provinces (British Columbia, Alberta, Ontario and Quebec). The final selection of primary care investigators was made after consultation with regional psychiatric consultants. A total of 48 primary care investigators (listed in Appendix 3) were identified who practised at 47 sites; each received extensive training on our study protocol and implementation. Details of the training and standards are in Appendix 2.
All primary care investigators were trained in good clinical practice guidelines. 20 Each site was approved by the Central Institutional Review Board (Aurora, Ont.) and the University of Alberta Research Board (Edmonton, Alta.). Upon completion of the study, all primary care investigators were asked to complete confidential questionnaires pertaining to the usefulness and time requirement to administer HAMD-7.
Eligible patients were assigned by means of computergenerated randomization numbers to HAMD-7 or HAMD-17 as the primary symptom-measurement tool before initiating 8 weeks of open-label, flexible-dose antidepressant monotherapy. Randomization was done at visit 2. Patients receiving an antidepressant for the first time or who required a change in antidepressant medication were eligible to participate. Visits after the baseline visit (which was visit 2) were scheduled every 2 weeks. Medications were chosen by the primary care investigators, in consultation with their patients, from the antidepressants available in Canada during the study (2003) (2004) : venlafaxine XR, citalopram, paroxetine, mirtazapine, fluoxetine, bupropion SR, sertraline and nefazodone. Although concomitant medications were permitted, patients could not be simultaneously enrolled in manual-based psychotherapy (e.g., cognitive behavioural therapy or interpersonal therapy) or receiving electroconvulsive therapy. Symptom severity was evaluated at each visit with either the HAMD-7 or HAMD-17 tool and with the Clinical Global Impression, Improvement or Severity of Illness scales (CGI-I/S). The MADRS test was administered at baseline (visit 2) and endpoint (visit 6).
At the end of the investigations, primary care investigators completed a HAMD-7 Rating Scale Investigator Evaluation Form, which requested an estimate of the average time required to administer HAMD-7 and qualitative comments about their satisfaction with the scale.
The study population (intent-to-treat), comprising all patients with a minimum of one postbaseline assessment, was analyzed with the last observation carried forward (LOCF) statistic. It was estimated that 375 evaluable patients were required to detect a small effect size ( 0.2) with a 2-tailed, paired t test (total HAMD-7 and HAMD-17 scores at the beginning and end of treatment) with a between-group correlation of 0.25, at a power of 80%. Assuming a 25% attrition of patients, a sample size of 500 patients was targeted initially.
For a comparison of scores evaluated with 2 related, but nevertheless different, measures of depression, a standard score was calculated for all postbaseline visits (i.e., for visits 3-6). For each HAMD-7 and HAMD-17 score acquired after randomization, the standard score (z) was calculated with the baseline group mean and its associated standard deviation (SD), HAMD- We evaluated changes over 8 weeks of antidepressant treatment in standard scores with a repeated measures analysis of variance (ANOVA) statistic with time as the within-subject factor and randomization as the between-subject factor. Differences at each visit were also evaluated with an independent-sample Student's t test. Convergent validity of HAMD-7 was evaluated via correlations between depressive symptom severity, overall change, response (> 50% reduction in pretreatment total MADRS + HAMD-17 scores) and remission of depressive symptoms (i.e., MADRS ≤ 10, HAMD-17 ≤ 7) and the CGI-I/S. A correlation coefficient corresponding to a p value < 0.001 was deemed clinically significant.
Response to therapy was defined as a reduction of 50% from pretreatment in depression symptom severity; remission was defined as a final score on HAMD-17 ≤ 7, HAMD-7 ≤ 3 and MADRS ≤ 10. Categorical data were analyzed with the χ 2 statistic. Dichotomous variables (i.e., response and remission status) were compared using Fisher's exact test. Pearson's correlation coefficient (r) with a 2-tailed test of significance was employed to quantify the agreement between the MADRS, HAMD-7 and HAMD-17 total scores. Spearman's correlation coefficients (ρ) were employed to compare HAMD-7 and HAMD-17 with the ordinal measures CGI-S and CGI-I. The internal consistency of HAMD-7 was evaluated with the Cronbach's α statistic for all measures of depression severity.
Results
Of 454 patients [164 males (36.1%) and 290 females (63.9%)] enrolled in the study (Fig. 1 ), a total of 410 were randomized to HAMD-7 (n = 205) or HAMD-17 (n = 205) as the primary symptom measurement scale ( Table 1) .
The mean total scores were 14.0 pretreatment to 5.31 at end point, for patients evaluated with HAMD-7; and 23.1 pretreatment to 8.06 at end point, for those evaluated with HAMD-17. The overall score reduction was highly significant (p < 0.001), measured with either rating scale ( Table 1) . Between-group differences in the percentage of patients responding or remitting with therapy in the HAMD-7 group (67% responding and 40% remitting) and the HAMD-17 group (74% and 49%, respectively) were nonsignificant (p = 0.43 and 0.17, respectively). There was also a significant pretreatment-to-endpoint change in the standardized HAMD-17 and HAMD-7 (p < 0.001), without a main effect of group (p = 0.84) or group-by-time interaction (p = 0.83), suggesting that sensitivity to change was similar for both scales. Within the group assigned to HAMD-17 as the primary symptom measurement tool, the items encompassed in the HAMD-7 scale were abstracted (HAMD-7A) and noted to highly correlate with HAMD-17 total scores (p < 0.001). Pretreatment-to-endpoint change in depressive symptom severity, response rate and remission rate for HAMD-7A and HAMD-17 were all significantly correlated (all p < 0.001).
The internal consistency of the HAMD-7, HAMD-7A and HAMD-17 ratings at each postbaseline visit was satisfactory and comparable (Table 2) . Comparison with the MADRS depression rating scale demonstrated that HAMD-7, HAMD-7A and HAMD-17 also showed satisfactory convergent validity in depressive symptom severity, overall change, response ( 50% reduction in pretreatment total MADRS score) and remission of depressive symptoms (MADRS ≤ 10) ( Table 3 ). The estimation of depressive symptom severity and change with treatment was also highly correlated between HAMD-7 and the CGI-I/S (Table 4) .
Of 48 physicians, 39 (82%) completed the HAMD-7 Rating Scale Investigator Evaluation Form. Physicians reported a high overall level of satisfaction with HAMD-7, noting that it was brief to administer (3-4 minutes for 85% of respondents), which facilitated the efficient and structured evaluation of salient depressive symptoms.
Interpretation
HAMD-7 was as sensitive as HAMD-17 in estimating the severity of depressive symptoms and evaluating the effectiveness of antidepressant treatment in a naturalistic primary care setting. The proportion of patients estimated to have achieved remission with HAMD-7 was statistically similar to the "gold standard" tool, the HAMD-17 rating scale. That the brevity of HAMD-7 did not appear to compromise vital information on patient progress and outcome was indicated by a high correlation with the multidimensional MADRS and CGI-I/S scales, and by acceptable levels of sensitivity and specificity. (Sensitivity, specificity and other psychometric properties are further described in a subsequent companion paper.)
Over the past decade, a fully asymptomatic state of remission has been emphasized as a critical end point in the management of depressed patients. A universally agreed-upon criterion for remission, however, does not currently exist, which belies the clinical utility of the remission concept. Notwithstanding, the proposed definition and operational criteria for remission (HAMD-17 ≤ 7) put forth by the McArthur Foundation group, 21 which is the definition of remission most cited, has served as a useful heuristic.
Several multinational expert guidelines on the management of depressive disorders emphasize remission, an outcome that transcends response, as an achievable and more clinically relevant symptomatic endpoint. 1,22-24 Residual depressive symptoms and incomplete remission are associated with early relapse, shorter duration between depressive episodes, chronicity, poor prognosis of comorbid medical disorders, increased use of medical services, sustained elevation of suicide risk, and psychosocial and functional deficits. 25 In the absence of a clinically useful and validated biological marker for remission in depression, clinicians are limited to empirically evaluating depressive symptoms and functional domains. 2 Paradoxically, most practitioners do not systematically evaluate patient progress with quantifiable measures. Although it is likely that clinical willingness to carefully track depressive symptoms is affected by multiple variables, it is likely that time-efficient tools would have greater acceptance in the field. Limitations of this validation study include the heterogeneity of patients enrolled and treatment assignment. For example, diagnostic criteria for a current major depressive episode was based on clinical judgment, and there was no rigorous control for comorbidity other than the exclusion criteria described above. Although the pretreatment MADRS scores were statistically significantly higher in the group randomized to HAMD-7, the differences between the groups are clinically insignificant. A further limitation is the presumption that the threshold scores of HAMD-17 ≤ 7 or MADRS ≤ 10 are prima facie evidence of depressive episode remission. It has been reported, for example, that depressed patients with HAMD-17 scores ≤ 7 may still manifest clinically significant disease activity. 26 On a further note, we chose HAMD-17 as the primary standard because it has been the most commonly employed and familiar metric both in clinical research on depression and among clinicians. An alternative methodology could have been to compare HAMD-7 to MADRS or to the global psychopathology measure, CGI. Lastly, for various reasons 44 patients withdrew from the study after randomization but before treatment began, and were not included in the analysis. Inclusion of these patients and ascribing them an outcome did not materially change the statistical results.
Research
In a busy primary care setting, self-administered scales 17,27 are an appealing alternative to MADRS, HAMD-17 and other lengthier depression metrics. Several studies, including a meta-analysis, have determined, however, that scales administered by clinicians may be more sensitive to change than self-rated measures, particularly in short-term studies. 28, 29 A practical and meaningful marker of remission should simultaneously evaluate both symptomatic and functional outcomes. HAMD-7 is primarily a symptom-measurement tool, inviting the need for additional monitoring of functional outcomes. Moreover, the mean doses of antidepressants in the study were at the lower end of the recommended ranges. However, it should be emphasized that the naturalistic setting, nonstandardization of treatment selection and patient heterogeneity in this study reflect real-world practice.
Conclusion
The HAMD-7 rating scale is the first brief-to-administer depression scale with a remission cut-off score validated in both specialty mental-health and primary care settings. The remission cut-off score (correlating with HAMD-17 ≤ 7) differentiates HAMD-7 from any other brief measure of depression that currently exists. A therapeutic target in the management of depression should be a HAMD-7 score ≤ 3; a vista for future research will be to establish if this objective measure corresponds with an absence of disease activity (e.g., as evinced by neuroimaging and neuroendocrine biomarkers). The routine clinical use of the HAMD-7 scale provides objective quantifiable evidence of depressive symptom severity, antidepressant effectiveness and remission of disease. HAMD-7 score ≥ 3 indicates full remission. HAMD-7 score ≤ 4 indicates non/partial response.
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